The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-6382
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660 ; volume:12 ; number:1 ; day:7 ; month:11 ; year:2022 ; pages:1-7 ; date:1.2023
Infectious diseases and therapy ; 12, Heft 1 (7.11.2022), 1-7, 1.2023
- Urheber
-
Orenstein, Robert
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40121-022-00714-9
- URN
-
urn:nbn:de:101:1-2023033021043738432407
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Orenstein, Robert
- SpringerLink (Online service)
Ähnliche Objekte (12)
Journal Summary: Microbiome-Based Therapies for Recurrent Clostridioides difficile
Mining the microbiome to modulate host defense against clostridioides difficile infections
Patient Education: Clostridioides difficile Infection
Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent Clostridioides difficile Infection
Editorial: Rejuvenating the Microbiome in Recurrent Clostridioides difficile Infection with Fecal Microbiota Transplant
Genomic characterization of nine Clostridioides difficile strains isolated from Korean patients with Clostridioides difficile infection
Globale genomische Epidemiologie von Clostridioides difficile
Gut metabolites predict Clostridioides difficile recurrence
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
Impact of ribotype on Clostridioides difficile diagnostics
Clostridioides Difficile Infection Presenting with Fulminant Colitis
Evidence-Based Commentary: Testing for Clostridioides difficile Infection
Journal Summary: Microbiome-Based Therapies for Recurrent Clostridioides difficile
Mining the microbiome to modulate host defense against clostridioides difficile infections
Patient Education: Clostridioides difficile Infection
Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent Clostridioides difficile Infection
Editorial: Rejuvenating the Microbiome in Recurrent Clostridioides difficile Infection with Fecal Microbiota Transplant
Genomic characterization of nine Clostridioides difficile strains isolated from Korean patients with Clostridioides difficile infection
Globale genomische Epidemiologie von Clostridioides difficile
Gut metabolites predict Clostridioides difficile recurrence
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
Impact of ribotype on Clostridioides difficile diagnostics
Clostridioides Difficile Infection Presenting with Fulminant Colitis
Evidence-Based Commentary: Testing for Clostridioides difficile Infection
Journal Summary: Microbiome-Based Therapies for Recurrent Clostridioides difficile
Mining the microbiome to modulate host defense against clostridioides difficile infections
Patient Education: Clostridioides difficile Infection
Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent Clostridioides difficile Infection
Editorial: Rejuvenating the Microbiome in Recurrent Clostridioides difficile Infection with Fecal Microbiota Transplant
Genomic characterization of nine Clostridioides difficile strains isolated from Korean patients with Clostridioides difficile infection
Globale genomische Epidemiologie von Clostridioides difficile
Gut metabolites predict Clostridioides difficile recurrence
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
Impact of ribotype on Clostridioides difficile diagnostics
Clostridioides Difficile Infection Presenting with Fulminant Colitis